

Article

Not peer-reviewed version

# Pyeloureteral Junction Obstruction: Underdevelopment or Fibrosis?

[Ramune Zilinskaite Tamasauske](#)\*, Vytis Kazlauskas, [Povilas Barasa](#), [Natalija Krestnikova](#), Darius Dasevicius, Vytautas Bilus, [Gilvydas Verkauskas](#)

Posted Date: 17 August 2023

doi: 10.20944/preprints202308.1229.v1

Keywords: Pyeloureteric junction; Pyeloureteric junction obstruction; Gene expression; Fibrosis related genes



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Article

# Pyeloureteral Junction Obstruction: Underdevelopment or Fibrosis?

Ramune Zilinskaite-Tamasauske <sup>1,\*</sup>, Vytis Kazlauskas <sup>1</sup>, Povilas Barasa <sup>2</sup>, Natalija Krestnikova <sup>2</sup>, Darius Dasevicius <sup>3</sup>, Vytautas Bilius <sup>1</sup> and Gilvydas Verkauskas <sup>1</sup>

<sup>1</sup> Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

<sup>2</sup> Vilnius University Life Sciences Center, Institute of Biochemistry, Vilnius, Lithuania

<sup>3</sup> Vilnius University Hospital Santaros Clinics, Centre of Pathology, Vilnius, Lithuania

\* Correspondence: ramune.zilinskaite-tamasauske@santa.lt; Tel.: +37061077264

**Abstract:** *Introduction:* congenital ureteral stenosis is one of the leading causes of impaired urinary drainage and subsequent dilatation of urinary collecting system, known as hydronephrosis or ureterohydronephrosis. Mechanism that leads to obstruction is not clearly known. Multiple studies in rat models have shown increased angiotensin II and TGF $\beta$  levels in obstructed ureteral tissue. The aim of the study is to investigate expression of fibrosis related genes in obstructive and normal ureteral tissue. *Material and methods:* it is a monocentric study in which nineteen patients were selected prospectively. 17 patients of which underwent Hynes-Anderson pyeloplasty due to the PUJO, 2 patients underwent ureteroneocystostomy due to ureterovesical junction obstruction (UVJO) and 6 patients were chosen for control group: 5 underwent nephrectomies due to the kidney tumor and 1- upper pole heminephrectomy due to the duplex kidney with normal pyeloureteric junctions in all. Tissue RNA was chemically extracted after freezing the biopsy samples in liquid nitrogen, with cDNA synthesis performed immediately after nucleic acid isolation. qPCR to evaluate the relative expression of Tgfb1, Mmp1, Timp1, Pai1, Ctgf and Vegfa was performed. Expression levels of Gapdh and Gpi genes (geometric average) were used to calculate the relative expression of the investigated genes. Outliers were removed prior to calculating confidence intervals for the experimental groups, and Wilcoxon rank-sum test was performed to determine statistical significance of the differences. *Results:* significant differences between healthy and stenotic tissue samples in Ctgf gene expression levels were observed, with the samples from afflicted tissue showing lower expression. No statistical difference in expression levels of Tgfb1, Timp1, Vegfa, Mmp1, Pai1 was found. *Discussion and conclusions:* These findings suggest that tissue fibrosis similar to other tissues and organs is not the leading cause of stenosis, at least at the moment of surgery. Decreased CTGF expression is indicative of developmental origin of obstruction.

**Keywords:** pyeloureteric junction; pyeloureteric junction obstruction; gene expression; fibrosis related genes

## 1. Introduction

Congenital ureteral stenosis is the leading cause of impaired urinary drainage and subsequent dilatation of urinary collecting system, condition known as hydronephrosis or ureterohydronephrosis, when ureteric dilatation is present. Ureteral obstruction is a very serious clinical condition, leading to damage of renal parenchyma because of obstruction induced increased pressure, reduced glomerular filtration, activation of profibrotic factors, cell apoptosis and subsequent loss of kidney function which has been investigated in animal models in a series of studies. [1], [2] Early recognition of obstruction, followed by timely treatment usually results in recovery of a kidney, mainly because of the better reproduction potential of renal stem cells and recovery of parenchyma at an early age. [3]

Several theories of pathogenesis leading to the development of hydronephrosis were learnt from animal models. The reasons of hydronephrosis can be generally regarded as obstructive and non-obstructive.

In systematic analysis which reviewed data from 10 articles was revealed that 15 genes had changed expression in ureteral stricture tissue. Genes which were up regulated were (ET1, 87 ACTA2, MCP-1, TGFB1, NFKB1, IL-6, HIF1A, S100A1, SYP) and the expression of six genes was down regulated (ADM, NOS2, EGF, PDGFRA, UCHL1, NGFR). The products of these genes are components of HIF-1 signaling pathway and participate in the development of vasculature. Some of these factors act as inductor of signaling pathways and particularly affect Ras signaling system. There may also be a connection of current factors with others that are related with tissue hypoxia, fibrosis and the inflammation. [4]

Histological studies of obstructed human ureters identified excessive amount of collagen in extracellular matrix and impaired distribution of its isoforms, increased proportion of elastin and apoptosis of myocytes. Altogether it leads to the abnormal development of tissue. [5], [6] In the intracellular level, immunofluorescence and PCR analysis revealed that cytoskeleton structural proteins were impaired in PUJO smooth muscle cells probably explaining the increased apoptosis of smooth muscle cells in PUJO specimens. [7] Aforementioned pathological findings suggest that the pathogenesis of the development of ureteral obstruction involves the processes of fibrosis, apoptosis and cell differentiation arrest.

The aim of our study was to analyze several fibrosis related factors that are known to participate in general mechanism of fibrosis in multiple sites of human body and to discuss their involvement in previously described chains of pathogenesis.

We have chosen to investigate fibrosis-associated genes expression in congenitally obstructed ureteral tissue. As obstruction involves abnormal cell differentiation as well as changes in extracellular matrix, expression profiles of *Tgfb1*, *Ctgf*, *Vegfa*, *Timp1*, *Pai1* and *Mmp1* genes were chosen to be analyzed according to previous studies where they were analyzed as the fibrosis inducing factors. [8–13] We could not identify any studies describing the expression analysis of CTGF, MMP1, PAI-1 in obstructed ureteral tissue over the last 10 years. Nevertheless, these genes were chosen as closely related to Tgfb pathway and implicated in the development of tissue fibrosis in other organs, such as the heart. [14]

## 2. Materials and Methods

### Collection of samples

It is a monocentric study in which patients were included prospectively from 2019 to 2021. Samples of pyeloureteric junctions and 2 ureterovesical junctions were collected during surgery and stored in -80°C until RNA extraction.

The decision of whether or not to operate on the patient was based on our local protocol: the operation was performed when there was an increase in the anterior-posterior diameter of renal pelvis by 20% on subsequent ultrasound scans, when the differential renal function (DRF) was <40% of the affected kidney or a decrease in DRF by >5% was observed on subsequent renal scans, or when symptoms could be attributed to hydronephrosis.

### RNA extraction and qPCR

Tissue RNA was extracted after freezing the samples in liquid nitrogen, mechanically dissociating them and applying Trizol reagent (*Thermo Fisher*) according to the manufacturer's protocol. 1 mL of Trizol reagent was added per 100 mg of tissue. Isolated RNA was dissolved in nuclease-free water, and its quantity and quality were evaluated using the NanoDrop device (*Thermo Fisher*).

cDNA synthesis was performed using Maxima H Minus First Strand cDNA Synthesis Kit (*Thermo Fisher*). Each sample had reverse transcription negative (RT-) control. qPCR was performed using Luminaris Color HiGreen qPCR Master Mix (*Thermo Fisher*) with the *Eppendorf realplex4* quantitative PCR device. Expression levels of *Gapdh* and *Gpi* genes (geometric average) were used to calculate relative expression of the investigated genes. The Common base method, as described in [15] was used to calculate relative expression of the genes, factoring the qPCR reaction efficiency. Primer sequences used for qPCR were derived from Primer Bank (<https://pga.mgh.harvard.edu/primerbank/>)


### Statistical analysis

Results were analyzed using RStudio Version 1.2.5033. Outliers were removed prior to analysis. Wilcoxon rank-sum test was carried out to determine the significance of differences between healthy and obstructed tissue (significance level  $\alpha = 0.05$ ), and assessment of confidence intervals was carried out to further understand the differences between the groups.

### 3. Results


17 patients underwent Hynes-Anderson pyeloplasty due to the PUJO, 2 patients underwent ureteroneocystostomy due to ureterovesical junction obstruction (UVJO). Six patients were chosen for control group: 5 underwent nephrectomies due to the kidney tumor and 1- upper pole heminephrectomy due to the duplex kidney with normal pyeloureteric junctions in all. Median age was 15.2 months [9.07; 66.2] at the time of the surgery and median age of control group (4 boys and 2 girls) was 60 months [35; 80.3].

The expression of fibrosis-related genes in every specimen are depicted in the heatmap. (Figure 1). Variable expression of all studied genes was noted both in obstructed and in normal junctions.



**Figure 2.** Relative expression of fibrosis-related genes in control and strictured ureter tissue samples. Medians (dot/triangle) and 95% confidence intervals (whiskers) shown. Star (\*) indicates statistical significance between the groups ( $p < 0.05$ ) as determined by Wilcoxon rank-sum test. Sample sizes are 6 for control and 19 for strictured group.

Wilcoxon rank-sum test showed significant differences between groups in *Ctgf* gene expression level. We further decided to compare the confidence intervals between groups, and the intervals of *Ctgf* gene showed little overlap, indicating differences between obstructed and control tissue samples. (Figure 2) No statistically significant differences between the groups were found in the expression of other studied genes.



**Figure 1.** Heatmap of relative expression of fibrosis-related genes in control and strictured ureter tissue samples. Results standardized to highest gene expression levels for each gene. PUJ – pyeloureteric junction obstruction; Tumor – pyeloureteric junction from kidney tumor specimen; Heminephr. – pyeloureteric junction from heminephrectomy specimen; VUJ – vesicoureteral junction obstruction.

4. Discussion

Out of our selected markers the best described group of fibrosis-related factors in the literature belong to transforming growth factor (TGF) family, particularly TGFs 1 to 3, sharing similar functions with minor structural differences. [16] Out of the three, the most well studied and ubiquitous is TGFβ1, a polypeptide that regulates cell differentiation, proliferation, adhesion and immune behavior. It is found in sites of injury, inflammation, cancer and elsewhere. The protein positively and negatively regulates other growth factors. The mature peptide may form heterodimers with other TGF beta family members. [17] It is stored in the extracellular matrix (ECM) as a complex with its pro-domain. Activation of TGFβ-1 requires the binding of alpha-V integrin, present on the membrane of residing cells, to an RGD sequence in the TGF prodomain and exertion of force on this domain, which is held in the extracellular matrix by latent TGFβ binding proteins (LTBP). As the synthesis and release of TGFβ involves many steps of proteolytic processing, binding and release, the expression and activity of TGFβ is both time and situation-dependent.

Among the disease-relevant ROS-dependent genomic targets (reactive oxygen species), TGF-beta1 stimulates expression of the potent profibrotic matricellular PAI-1 and CTGF genes as well as those that code ECM structural elements (fibronectin, collagen I). PAI-1 is one of the most highly regulated part of the TGFβ1/SMAD3-induced group, a prominent ROS responsive gene and involved in tissue fibrosis process. As the main inhibitor of plasmin generation, PAI-1 limits ECM degradation alleviating accumulation of matrix structural elements at the injury site. PAI-1 deficiency is renal-protective whereas transgenic PAI-1 overexpression promotes an increased fibrotic response with associated recruitment of inflammatory cells, macrophages and myofibroblasts. As proof-of-concept, unilateral ureter-obstructed PAI-1<sup>-/-</sup> mice develop a significantly attenuated inflammatory response suggesting that PAI-1 directly promotes infiltration of macrophages and T-cells. [17]



However, it is worth mentioning that out of these studies we could identify only one when polymerase chain reaction (PCR) analysis was applied in human ureters and showed that the amount of TGF $\beta$ 1 mRNA in stenotic tissue was higher than in controls. [18] Another study found that immunohistochemical staining of TGF $\beta$ 3 in obstructed tissue was higher than in the control tissue. [19] Even though the results of our study of TGF $\beta$  in patients with PUJO could not replicate these findings, this could be due to the observations that TGF $\beta$ 1 is often expressed in the early stages of diseases, especially when macrophage activity is high, as well as when inflammation is present. Experimental studies have also advocated the increase of mRNA TGF- $\beta$  in postoperative UPJO. Under these circumstances such finding can be explained by an acute onset of obstruction activating muscle fiber and collagen elaboration. [20]

We found only one study analyzing the role of PAI-1 in an obstructed kidney model and showing that TIMP-1 and PAI-1 in rat model are involved in the progression of tubulointerstitial scarring of renal tissue. [21]

With regard to one of the theories of UB branching, AngII is named as one of the enhancers for this process. PAI-1 has also been described as a downstream target of AngII in endothelial cells. [22] Is there a relation between potentially decreased PAI-1 and AngII, as its potential effector in congenitally obstructed ureter, remains to be answered. PAI-1 has been shown to play a role in ECM maintenance and remodeling, counteracting the effects of matrix metalloproteinases. [23]

We were able to identify only one study where VEGF was investigated in UPJO and a control group in human specimens: no color staining of VEGF was found in both obstructed and control groups and subsequently showed no difference in staining potential regardless of obstruction pattern. [24] Our results in VEGF expression have corresponded to the results of an aforementioned study, finding no difference in this gene expression in stenotic versus healthy tissue.

We could not identify any previous publication regarding Ctgf expression profile in congenital ureteral obstruction.

Our results have demonstrated that relative expression of Ctgf in stenotic ureteral tissue was significantly lower than in the control tissue supporting a potential role of this gene in the processes of stricture development. Ctgf has important roles in many biological processes, including cell adhesion, migration, proliferation, angiogenesis, skeletal development, and tissue wound repair, and is critically involved in fibrotic disease and several forms of cancers [9], [25]. It is thought that CTGF can cooperate with TGF $\beta$  to induce fibrosis and extracellular matrix production in association with other fibrosis-related conditions. [26] Overexpression of Ctgf in fibroblasts promotes fibrosis at the beginning of the development of stricture in the skin, kidney, and lung. We may only speculate that the reduction in our patients may be indicative on the stage of fibrosis – for example, in a nephropathy model in mice, it was shown that the expression level of Ctgf gradually increases over a 2-week period and is static afterwards; our results indicate there may be a significant reduction in the expression of this gene following the primary stage of disease development or gene can be only expressed for a certain period of time. [27]

Evident similarity in expression of other studied genes may suggest that fibrosis process is not the most important in the development of congenital PUJO and we should rather concentrate on other aspects of development.

Considering other aspects of cell distribution, the most prominent alteration comprises interstitial cells of Cajal and telocytes which are significantly reduced in comparison to normal ureteral tissue in both UPJO and UVJO. Differentiation of Cajal cells may be stimulated by overexpression of CTGF gene. [28] Also, SOX9 was found regulating CTGF/CCN2 transcription in chondrocytes. [29] Hypomotility of the ureter was induced by *Sox9*, a homeobox gene, the loss of which led to smooth muscle cell differentiation arrest. [30] Another study showed an essential role of Sox9 in regulation of differentiation of ureteric mesenchyme. Primary dilatation of renal collecting system without ureteral obstruction was induced by *Keap1* knockout and expression of aquaporins with spontaneous mutations which caused urinary hyperproduction and secondary dilatation of renal collecting system. [31]

The drawback of our study is the relatively low and heterogeneous by age sample size. Although statistical analysis was possible, more specimens would be needed to elucidate the potential

differences in the expression of our studied genes. Another drawback is a small and non-homogenous control group when 5 pyeloureteric junctions were obtained from renal tumor specimens and 1 pyeloureteric junctions from duplex kidney system. None of them had macroscopic signs of stricture, however the results can be influenced by preoperative chemotherapy and maldevelopment of the ureteral wall when compared to normal ureters. [32] Observed tendencies comparing PUJ, UVJ, dilated UVJ and normal PUJ after chemotherapy may be further investigated.

In summary, our findings suggest that decreased *Ctgf* expression in strictured ureteral specimen may be a sign of a progressive failure determined by a genetic trigger occurring at the embryonic period. Further studies have to be conducted to verify hypotheses.

## 5. Conclusions

In summary, our findings suggest that decreased *Ctgf* expression in strictured ureteral specimen may be a sign of a progressive failure determined by a genetic trigger occurring at the embryonic period. Further studies have to be conducted to verify hypotheses.

**Author Contributions:** All authors have accepted responsibility for the entire content of this manuscript and approved its submission. All authors prepared the manuscript.

**Funding:** This project has received funding from European Regional Development Fund No 01.2.2-LMT-K-718-03-0087 under grant agreement with the Research Council of Lithuania (LMTLT).

**Institutional Review Board Statement:** This study was approved by the Vilnius Regional Bioethics Committee (158200-18/6-1044-544, the date of approval 05/06/2018).

**Conflicts of Interest:** None.

## Abbreviations

UB	ureteric bud;
PUJO	obstructed pyeloureteric junction;
EGFR	epidermal growth factor receptor;
AT1R	angiotensin type 1 receptor;
AT2R	angiotensin type 2 receptor;
UVJO	ureterovesical junction obstruction;
ChKD	chronic kidney disease;
ESRD	end stage renal disease;
LTBP	latent TGF $\beta$ binding proteins

## References

1. Zhao S. *et al.*, "Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys," *Theranostics*, vol. 11, no. 18, pp. 8660–8673, 2021, doi: 10.7150/thno.62820.
2. Chang I.Y. *et al.*, "Repression of apurinic/aprimidinic endonuclease by p53-dependent apoptosis in hydronephrosis-induced rat kidney," *Free Radic Res*, vol. 45, no. 6, pp. 728–734, Jun. 2011, doi: 10.3109/10715762.2011.574289.
3. Deng Q.F., Chu H, Peng B, Liu X, and Cao YS, "Outcome analysis of early surgery and conservative treatment in neonates and infants with severe hydronephrosis," *Journal of International Medical Research*, vol. 49, no. 11, 2021, doi: 10.1177/03000605211057866.
4. Isali I, McClellan P, Wong TR, Gupta S, and Woo L, "A systematic review of underlying genetic factors associated with ureteropelvic junction obstruction in stenotic human tissue," *Journal of Pediatric Urology*, vol. 18, no. 5. Elsevier Ltd, pp. 629–641, Oct. 01, 2022. doi: 10.1016/j.jpuro.2022.07.022.
5. Senkul T. *et al.*, "The smooth muscle ratio at the renal pelvis in adults: does it predict surgical outcome?" *Urol Int*, vol. 73, no. 3, pp. 248–251, 2004, doi: 10.1159/000080836.

6. Kajbafzadeh A.M., Payabvash S., Salmasi A.H., Monajemzadeh M., and Tavangar S.M., "Smooth muscle cell apoptosis and defective neural development in congenital ureteropelvic junction obstruction.," *J Urol*, vol. 176, no. 2, pp. 718–23; discussion 723, Aug. 2006, doi: 10.1016/j.juro.2006.03.041.
7. Wishahi M. *et al.*, "SMOOTH MUSCLE CELLS AND COLLAGEN FIBRES ARCHITECTURE IN EQUIVOCAL URETEROPELVIC JUNCTION OBSTRUCTION: ELECTRON MICROSCOPY STUDY WITH CLINICAL CORRELATION IN ADULT EGYPTIANS," 2020.
8. Hinz B., "The extracellular matrix and transforming growth factor- $\beta$ 1: Tale of a strained relationship," *Matrix Biology*, vol. 47, pp. 54–65, 2015, doi: 10.1016/j.matbio.2015.05.006.
9. Lipson K.E., Wong C, Teng Y, and Spong S, "CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis," *Fibrogenesis Tissue Repair*, vol. 5, no. S1, pp. 2–9, 2012, doi: 10.1186/1755-1536-5-s1-s24.
10. Shang J. *et al.*, "miR-15a-5p suppresses inflammation and fibrosis of peritoneal mesothelial cells induced by peritoneal dialysis via targeting VEGFA," *J Cell Physiol*, vol. 234, no. 6, pp. 9746–9755, Jun. 2019, doi: 10.1002/jcp.27660.
11. Nie Q.H. *et al.*, "Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis," *World J Gastroenterol*, vol. 10, no. 1, pp. 86–90, 2004, doi: 10.3748/wjg.v10.i1.86.
12. Ghosh A.K. and Vaughan D.E., "PAI-1 in tissue fibrosis," *J Cell Physiol*, vol. 227, no. 2, pp. 493–507, 2012, doi: 10.1002/jcp.22783.
13. Mahmoud A.A., Bakir A.S., and Shabana S.S., "Serum TGF- $\beta$ , serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD," *Saudi Journal of Gastroenterology*, vol. 18, no. 5, pp. 327–333, Sep. 2012, doi: 10.4103/1319-3767.101132.
14. Ladouceur M. *et al.*, "Role of myocardial collagen degradation and fibrosis in right ventricle dysfunction in transposition of the great arteries after atrial switch," *Int J Cardiol*, vol. 258, pp. 76–82, 2018, doi: <https://doi.org/10.1016/j.ijcard.2018.01.100>.
15. Ganger M.T., Dietz G.D., and Ewing S.J., "A common base method for analysis of qPCR data and the application of simple blocking in qPCR experiments," *BMC Bioinformatics*, vol. 18, no. 1, p. 534, 2017, doi: 10.1186/s12859-017-1949-5.
16. Horbelt D., Denkis A., and Knaus P., "A portrait of Transforming Growth Factor  $\beta$  superfamily signalling: Background matters," *Int J Biochem Cell Biol*, vol. 44, no. 3, pp. 469–474, 2012, doi: <https://doi.org/10.1016/j.biocel.2011.12.013>.
17. Samarakoon R., Overstreet J.M., and Higgins P.J., "TGF- $\beta$  signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.," *Cell Signal*, vol. 25, no. 1, pp. 264–268, Jan. 2013, doi: 10.1016/j.cellsig.2012.10.003.
18. Yang Y., Zhou X., Gao H., Ji S.J., and Wang C., "The expression of epidermal growth factor and transforming growth factor-beta1 in the stenotic tissue of congenital pelvi-ureteric junction obstruction in children.," *J Pediatr Surg*, vol. 38, no. 11, pp. 1656–1660, Nov. 2003, doi: 10.1016/s0022-3468(03)00577-3.
19. Koca O., Kaya C., Ozturk M.I., Gunes M., Gumrukcu G., and Karaman M.I., "Analysis of expression of TNF-alpha and TGF-beta3 in intrinsic ureteropelvic junction obstruction.," *Bratisl Lek Listy*, vol. 114, no. 9, pp. 498–502, 2013, doi: 10.4149/bll\_2013\_104.
20. Seremetis G.M. and Maizels M., "TGF-beta mRNA expression in the renal pelvis after experimental and clinical ureteropelvic junction obstruction.," *J Urol*, vol. 156, no. 1, pp. 261–266, Jul. 1996.
21. Duymelinck C., Dauwe S.E., De Greef K.E., Ysebaert D.K., Verpooten G.A., and De Broe M.E., "TIMP-1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult male rat.," *Kidney Int*, vol. 58, no. 3, pp. 1186–1201, Sep. 2000, doi: 10.1046/j.1523-1755.2000.00274.x.
22. Vaughan D.E., Luzzo S.A., and Tong K., "Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.," *J Clin Invest*, vol. 95, no. 3, pp. 995–1001, Mar. 1995, doi: 10.1172/JCI117809.
23. Ghosh A.K. and Vaughan D.E., "PAI-1 in tissue fibrosis.," *J Cell Physiol*, vol. 227, no. 2, pp. 493–507, Feb. 2012, doi: 10.1002/jcp.22783.
24. Magyar Z. *et al.*, "Expression of VEGF in neonatal urinary obstruction: does expression of VEGF predict hydronephrosis?" *Med Sci Monit*, vol. 21, pp. 1319–1323, May 2015, doi: 10.12659/MSM.894133.
25. Bickelhaupt S. *et al.*, "Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis," *J Natl Cancer Inst*, vol. 109, no. 8, Aug. 2017, doi: 10.1093/jnci/djw339.
26. Valle-Tenney R., Rebolledo D.L., Lipson K.E., and Brandan E., "Role of hypoxia in skeletal muscle fibrosis: Synergism between hypoxia and TGF- $\beta$  signaling upregulates CCN2/CTGF expression specifically in muscle fibers," *Matrix Biology*, vol. 87, pp. 48–65, May 2020, doi: 10.1016/j.matbio.2019.09.003.
27. Roestenberg P. *et al.*, "Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice," *Am J Physiol Renal Physiol*, vol. 290, no. 6, 2006, doi: 10.1152/ajprenal.00174.2005.
28. Wang X. and Cretoiu D., "Advances in Experimental Medicine and Biology 913 Telocytes Connecting Cells." [Online]. Available: <http://www.springer.com/series/5584>



29. Huang B.L., Brugger S.M., and Lyons K.M., "Stage-specific control of connective tissue growth factor (CTGF/CCN2) expression in chondrocytes by Sox9 and  $\beta$ -catenin," *Journal of Biological Chemistry*, vol. 285, no. 36, pp. 27702–27712, Sep. 2010, doi: 10.1074/jbc.M110.108498.
30. Airik R. *et al.*, "Hydroureteronephrosis due to loss of Sox9-regulated smooth muscle cell differentiation of the ureteric mesenchyme," *Hum Mol Genet*, vol. 19, no. 24, pp. 4918–4929, Dec. 2010, doi: 10.1093/hmg/ddq426.
31. Ampawong S. *et al.*, "Expression of aquaporin-1, -2 and -4 in mice with a spontaneous mutation leading to hydronephrosis," *J Comp Pathol*, vol. 146, no. 4, pp. 332–337, May 2012, doi: 10.1016/j.jcpa.2011.08.005.
32. Paces-Fessy M., Fabre M., Lesaulnier C., and Cereghini S., "Hnf1b and Pax2 cooperate to control different pathways in kidney and ureter morphogenesis," *Hum Mol Genet*, vol. 21, no. 14, pp. 3143–3155, Jul. 2012, doi: 10.1093/hmg/dds141.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.